A review article was recently published by Sebastien Jacquelin et al, covering the history and important contributions of mouse models to our understanding of myeloproliferative neoplasms. Preclinical models such as those described in this manuscript have provided important information about the impact of primary driver gene dosage and the role of secondary genetic mutations as factors increasing the risk for progression to myelofibrosis (MF). Additionally, these models also enable the rational testing of new therapeutics and drug combinations that can target the identified pathways driving MF disease evolution. The MPNRF has long been a supporter MPN mouse model development and we are pleased that two of the authors, Drs. Steven Lane and Ann Mullally acknowledged our support in this article. Drs. Lane and Mullally are part of our Interferon Initiative research collaboration.